| Vol. 15.37 – 28 September, 2023 |
| |
|
|
| The authors developed a novel technique to directly bioprint 3D cell-laden prevascularized construct. They developed a novel bioink by mixing decellularized human amniotic membrane and alginate in various ratios. [International Journal Of Biological Macromolecules] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| In this randomized and placebo-controlled trial, a total of 73 patients were randomly assigned to receive intravenous infusion of umbilical cord-derived mesenchymal stem cells or placebo, three times at four-week intervals and followed up for 48 weeks. [Stem Cells Translational Medicine] |
|
|
|
| The authors established CD34+ cord blood-derived CBFA2T3::GLIS2 models that sustained serial transplantation and recapitulated human leukemia regarding immunophenotype. [Blood Advances] |
|
|
|
| Researchers investigated for the first time the role of gut microbiota in mediating the protective effect of human umbilical cord MSCs on 2% dextran sodium sulfate-induced colitis. [Current Stem Cell Research & Therapy] |
|
|
|
| Umbilical cord MSCs were cultured in vitro and apoptosis was induced. Apoptotic extracellular vesicles were extracted and identified and used in a type 2 diabetes mellitus mouse cutaneous wound model to evaluate their efficacy. [Stem Cell Research & Therapy] |
|
|
|
| Decellularized Wharton’s Jelly was dissolved to make Wharton’s Jelly Hydrogel, and composited with Alginate in equal ratio. [PLOS One] |
| |
|
|
|
| Investigators conducted a systemic literature review was conducted by searching the Cochrane Library and PubMed databases for articles that evaluated the impact of MSC therapy on the outcomes among patients with end-stage liver disease. [Stem Cell Research & Therapy] |
|
|
|
|
| The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee has voted that current data on NurOwn, BrainStorm Cell Therapeutics’ stromal cell therapy, is not sufficient in demonstrating efficacy as a treatment for patients with mild to moderate amyotrophic lateral sclerosis (ALS). [NeurologyLive] |
|
|
|
|
| October 29 – November 1, 2023 New York, New York, United States |
|
|
|
|
|
| University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| Stanford University – Stanford, California, United States |
|
|
|
| ShanghaiTech University – Shanghai, China |
|
|
|
| UT Southwestern Medical Center – Dallas, Texas |
|
|
|
| University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
|